Interim data from the Phase 2/3 clinical trial of Tempol did not demonstrate statistical significance of its primary endpoint of clinical resolution of COVID-19 symptoms at day 14 versus placebo
Independent Data Safety Monitoring Board recommends halting the trial
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.